Pirjo Laakkonen

ORCID

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 13

Top Venues

Cancers

Molecular pharmaceutics

Molecular cancer therapeutics

Pharmaceutics

University of Helsinki (PHD)

This page only lists publications with an associated author ORCID identifier.

Education History

University of Helsinki

Finland

PHD :: Institute of Biotechnology

Publications

Pyry Dillemuth, Petter Lövdahl, Tuomas Karskela, Abiodun Ayo, Jesse Ponkamo, Heidi Liljenbäck, Sami Paunonen, Jonne Kunnas, Johan Rajander, Olli Tynninen, Jessica M Rosenholm, Anne Roivainen, Pirjo Laakkonen, Anu J Airaksinen, Xiang-Guo Li
Switching the Chemoselectivity in the Preparation of [ 18 F]FNA- N -CooP, a Free Thiol-Containing Peptide for Targeted Positron Emission Tomography Imaging of Fatty Acid Binding Protein 3. Molecular pharmaceutics 21 (8) (2024)
Pyry Dillemuth, Petter Lövdahl, Tuomas Karskela, Abiodun Ayo, Jesse Ponkamo, Heidi Liljenbäck, Sami Paunonen, Jonne Kunnas, Johan Rajander, Olli Tynninen, Jessica M Rosenholm, Anne Roivainen, Pirjo Laakkonen, Anu J Airaksinen, Xiang-Guo Li
Switching the Chemoselectivity in the Preparation of [ 18 F]FNA- N -CooP, a Free Thiol-Containing Peptide for Targeted Positron Emission Tomography Imaging of Fatty Acid Binding Protein 3. Molecular pharmaceutics (2024)
Hector J Monzo, Kerttu Kalander, Marko M Hyytiäinen, Endrit Elbasani, Johanna Wall, Lidia Moyano-Galceran, Jayendrakishore Tanjore Ramanathan, Joonas J J Jukonen, Pirjo Laakkonen, Ari Ristimäki, Joseph W Carlson, Kaisa Lehti, Sahar Salehi, Pauli Puolakkainen, Caj Haglund, Hanna Seppänen, Sirpa Leppa, Päivi M Ojala
Efficacy and safety of glycosphingolipid SSEA-4 targeting CAR-T cells in an ovarian carcinoma model. Molecular cancer therapeutics (2023)
Lennard Karsten, Nils Janson, Vadim Le Joncour, Sarfaraz Alam, Benjamin Müller, Jayendrakishore Tanjore Ramanathan, Pirjo Laakkonen, Norbert Sewald, Kristian M Müller
Bivalent EGFR-Targeting DARPin-MMAE Conjugates. International journal of molecular sciences 23 (5) (2022)
Abiodun Ayo, Pirjo Laakkonen
Peptide-Based Strategies for Targeted Tumor Treatment and Imaging. Pharmaceutics 13 (4) (2021)
Denis Belitškin, Shishir M Pant, Pauliina M Munne, Ilida Suleymanova, Kati Belitškina, Hanna-Ala Hongisto, Johanna I Englund, Tiina Raatikainen, Olga Klezovitch, Valeri Vasioukhin, Shuo Li, Qingyu Wu, Outi Monni, Satu Kuure, Pirjo Laakkonen, Jeroen Pouwels, Topi A Tervonen, Juha Klefström
Hepsin regulates TGFβ signaling via fibronectin proteolysis. EMBO reports 22 (11) (2021)
Neeraj Prabhakar, Joni Merisaari, Vadim Le Joncour, Markus Peurla, Didem Şen Karaman, Eudald Casals, Pirjo Laakkonen, Jukka Westermarck, Jessica M Rosenholm
Circumventing Drug Treatment? Intrinsic Lethal Effects of Polyethyleneimine (PEI)-Functionalized Nanoparticles on Glioblastoma Cells Cultured in Stem Cell Conditions. Cancers 13 (11) (2021)
Nicolò Tonali, Loreen Hericks, David C Schröder, Oliver Kracker, Radosław Krzemieniecki, Julia Kaffy, Vadim Le Joncour, Pirjo Laakkonen, Antoine Marion, Sandrine Ongeri, Veronica Isabel Dodero, Norbert Sewald
Peptidotriazolamers Inhibit Aβ(1-42) Oligomerization and Cross a Blood-Brain-Barrier Model. ChemPlusChem 86 (6) (2021)
Abiodun Ayo, Eduard Figueras, Thomas Schachtsiek, Mazlum Budak, Norbert Sewald, Pirjo Laakkonen
Tumor-Targeting Peptides: The Functional Screen of Glioblastoma Homing Peptides to the Target Protein FABP3 (MDGI). Cancers 12 (7) (2020)
Vadim Le Joncour, Pauliina Filppu, Maija Hyvönen, Minna Holopainen, S Pauliina Turunen, Harri Sihto, Isabel Burghardt, Heikki Joensuu, Olli Tynninen, Juha Jääskeläinen, Michael Weller, Kaisa Lehti, Reijo Käkelä, Pirjo Laakkonen
Vulnerability of invasive glioblastoma cells to lysosomal membrane destabilization. EMBO molecular medicine 11 (6) (2020)
Jayendrakishore Tanjore Ramanathan, Suvi Lehtipuro, Harri Sihto, József Tóvári, Lilla Reiniger, Vanda Téglási, Judit Moldvay, Matti Nykter, Hannu Haapasalo, Vadim Le Joncour, Pirjo Laakkonen
Prostate-specific membrane antigen expression in the vasculature of primary lung carcinomas associates with faster metastatic dissemination to the brain. Journal of cellular and molecular medicine 24 (12) (2020)
Vadim Le Joncour, Ana Martins, Maija Puhka, Jorma Isola, Marko Salmikangas, Pirjo Laakkonen, Heikki Joensuu, Mark Barok
A Novel Anti-HER2 Antibody-Drug Conjugate XMT-1522 for HER2-Positive Breast and Gastric Cancers Resistant to Trastuzumab Emtansine. Molecular cancer therapeutics 18 (10) (2019)
Eduard Figueras, Ana Martins, Adina Borbély, Vadim Le Joncour, Paola Cordella, Raffaella Perego, Daniela Modena, Paolo Pagani, Simone Esposito, Giulio Auciello, Marcel Frese, Paola Gallinari, Pirjo Laakkonen, Christian Steinkühler, Norbert Sewald
Octreotide Conjugates for Tumor Targeting and Imaging. Pharmaceutics 11 (5) (2019)

Pirjo Laakkonen.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Pirjo Laakkonen